HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target

HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Enanta Pharma (NASDAQ: ENTA) and maintained a price target of $20. This endorsement suggests confidence in the company's future performance.